Biomea Fusion's Icovamenib Shows Durable Diabetes Benefits Nine Months After Treatment Ends
Key Insights
Biomea Fusion presented COVALENT-111 study results showing icovamenib, a menin (search) inhibitor, demonstrated durable glycemic and C-peptide improvements in insulin-deficient type 2 diabetes (search) patients nine months after the last dose.
The investigational drug showed higher HbA1c reduction associated with higher exposure levels and improved long-term insulin secretion in severe insulin-deficient T2D patients.
Icovamenib was generally well-tolerated with no adverse-event related discontinuations and no related serious adverse events, representing a first-in-class approach targeting beta-cell restoration.
Biomea Fusion presented compelling long-term data for its investigational diabetes (search) drug icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles, demonstrating sustained therapeutic benefits nine months after treatment cessation. The COVALENT-111 study results showed durable glycemic and C-peptide improvements in patients with insulin-deficient type 2 diabetes (search), marking a significant milestone for the first-in-class menin (search) inhibitor.
"Over the past 24 months, our clinical studies have shown that selective inhibition of menin (search) can meaningfully influence the clinical response of patients with insulin deficient diabetes (search)," said Mick Hitchcock, Ph.D., Interim CEO and Board Member of Biomea Fusion. "The results we presented at this meeting highlight the lasting and continuous benefits observed in our study, with durable glycemic and C-peptide improvements 9 months after the last dose."
Key Clinical Findings at Week 52
The WCIRDC presentation highlighted several critical outcomes measured at week 52, representing nine months post the final dose administration. Icovamenib demonstrated a durable and continuous treatment effect in severe insulin-deficient type 2 diabetes (search) patients. Notably, higher HbA1c reduction was associated with higher icovamenib exposure, suggesting a dose-response relationship that could inform optimal dosing strategies.
The drug improved long-term insulin secretion in severe insulin-deficient T2D patients, addressing a fundamental pathophysiological deficit in this patient population. Treatment effects in GLP-1 "failures" continued to improve with durable and clinically significant improvements in HbA1c, indicating potential utility in patients who have not responded adequately to current standard-of-care therapies.
Safety Profile and Tolerability
Icovamenib demonstrated a favorable safety profile throughout the study period. The drug was generally well-tolerated, with no adverse-event related discontinuations and no related serious adverse events reported. This safety profile supports the potential for broader clinical development and eventual therapeutic application.
Novel Mechanism of Action
Icovamenib represents an investigational, orally bioavailable, potent, and selective covalent inhibitor of menin (search). The proposed mechanism of action involves selective and partial inhibition of menin, a regulator of beta cell quantity and function, thereby enabling the proliferation, preservation, and reactivation of patients' own healthy, functional, insulin-producing beta cells.
"Targeting menin (search) offers promise for people living with diabetes (search), with the potential to support the natural insulin producing capacity of the pancreatic beta cells," Hitchcock explained. "Icovamenib, as a selective menin inhibitor, represents a first in class approach in this area of research."
Study Design and Patient Population
COVALENT-111 is a double-blind, randomized, placebo-controlled trial that enrolled adult patients diagnosed with T2D within the last seven years. Eligible participants had HbA1c levels between 7.0% and 10.5%, and a body mass index (BMI) between 25 and 40 kg/m². At baseline, all participants were treated with lifestyle management, including diet and exercise, with or without antidiabetic medications and had inadequate glycemic control despite treatment with up to three antidiabetic medications.
The study evaluated icovamenib in three dosing regimens: Arm A at 100mg once daily for 8 weeks, Arm B at 100mg once daily for 12 weeks, and Arm C at 100mg once daily for 8 weeks followed by 100mg twice daily for 4 weeks.
Future Development Plans
As the first non-chronic therapy for T2D, icovamenib could become an important addition to the diabetes (search) treatment landscape once it successfully completes ongoing clinical studies. Biomea Fusion plans to initiate a Phase IIb trial (COVALENT-211) in severe insulin-deficient type 2 diabetes (search) patients and a Phase II trial with GLP-1 therapy (COVALENT-212) in type 2 diabetes patients, both scheduled to begin in the fourth quarter of 2025.
The abstract from the WCIRDC presentation will be published in the peer-reviewed journal Metabolism: Experimental and Clinical, providing broader scientific access to these findings. Biomea Fusion, a clinical-stage biopharmaceutical company, is advancing oral small molecule therapies for diabetes (search) and obesity (search), targeting metabolic disorders that affect nearly half of Americans and one-fifth of the world's population.